covid vaccine and semaglutide Study finds weight loss drug reduced COVID-19 related deaths during the pandemic Patients fear losing access to

e Information collected at screening on comorbidities was based on medical history and included: type 2 diabetes (STEP 2 only), dyslipidaemia, hypertension, coronary artery disease, cerebrovascular disease, obstructive sleep apnoea, impaired glucose metabolism (not included for STEP 2), reproductive system disorders, liver disease, kidney disease, osteoarthritis, gout, thyroid disease (STEP 3 only) and asthma or chronic obstructive pulmonary disease

Important Note: Semaglutide injections are needed to be prescribed by your healthcare provider

Regular monitoring is essential

Semaglutide GLP-1 injections are approved by the FDA for chronic weight management in adults who have a body mass index (BMI) of 27 kg/m or greater and at least one weight-related medical condition